Lee Han Myung 4

What Happened

• Lee Han Myung, a director of Century Therapeutics, was granted 74,000 derivative shares (an equity award) on June 11, 2026. The filing reports an acquisition price of $0.00 for the award (derivative transaction), meaning no cash was paid as part of this grant. This is a compensatory equity award, not a market purchase or sale.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-12 (timely).
• Amount: 74,000 shares; reported acquisition price: $0.00; transaction type: Grant/Award (derivative).
• Shares owned after transaction: not specified in the filing.
• Footnote: The award vests on the earlier of (a) June 11, 2027 or (b) the next annual meeting of stockholders, subject to the director’s continued service through the applicable vesting date (see footnote F1).
• No indication of a 10b5-1 plan, cashless exercise, tax withholding sale, or late filing in the report.

Context

• This grant appears to be a standard equity award for a director tied to continued service via a vesting schedule. Such awards are compensation and do not represent an immediate market buy or sell. For investors, purchases or open-market buys by insiders can be more indicative of personal conviction; awards are routine but still increase potential future insider ownership if vested and exercised.